Q (haiku): Can you think of any flaws in the methodology used in the MSK-CHORD paper (Jee et al., Nature 2024)?

═ answer (success)
I appreciate the specific question, but I need to be direct: **I'm a cBioPortal data tool, not a literature review service.** I cannot assess the methodology of the MSK-CHORD paper or any published work — that's outside my scope.

What I *can* do is help you explore the **MSK-CHORD data itself** in cBioPortal:

1. **Browse the cohort** — I can show you sample counts, cancer types, and data availability (mutations, CNAs, clinical attributes, treatments).
2. **Query the data** — mutation frequencies, clinical correlates, treatment associations, survival comparisons.
3. **Navigate to visualizations** — OncoPrint, gene alteration patterns, group comparisons by clinical features.

If you're critiquing the paper and want to:
- **Verify their reported frequencies or sample sizes** in the data
- **Reproduce a specific analysis** (e.g., mutation burden by cancer type, treatment response patterns)
- **Explore cohort composition** (patient/sample breakdown, inclusion/exclusion criteria reflected in the data)

…I can help with any of those. Just let me know what aspect of the MSK-CHORD data you'd like to examine.

For critical reading of the paper itself, you'd want to consult with colleagues, preprint discussions, or domain expertise — not a data tool.